SIGLEC12 and breast cancer: The physical interaction between SIGLEC12 and phospholipase A2-activating protein (PLAA), a gene that is downregulated in aggressive metastatic ovarian cancer cells [65], suggested an oncogenic function of SIGLEC12. Other studies have also implicated PLAA inactivation to the development of lung, and breast cancer [66].